|
Treatment
|
Reference
|
Odds ratio (95 % CrI)
|
Relative risk (95 % CrI)
|
Risk difference % (95 % Crl)
|
|---|
|
CYC
|
PRED
|
2.35 (1.28, 4.23)
|
1.60 (1.60, 2.24)
|
0.21 (0.06, 0.34)
|
|
MMF
| |
3.26 (1.57, 6.72)
|
1.82 (1.82, 2.60)
|
0.28 (0.11, 0.44)
|
|
TAC
| |
2.51 (1.11, 5.76)
|
1.64 (1.64, 2.44)
|
0.22 (0.03, 0.41)
|
|
CSA
| |
5.69 (2.02, 17.61)
|
2.15 (2.15, 3.18)
|
0.40 (0.17, 0.58)
|
|
CYC LD
|
CYC
|
0.32 (0.10, 0.89)
|
0.51 (0.51, 0.95)
|
−0.26 (−0.45, −0.03)
|
|
CYC LD
|
MMF
|
0.23 (0.08, 0.61)
|
0.45 (0.45, 0.81)
|
−0.34 (−0.53, −0.12)
|
|
CYC HD
| |
0.40 (0.20, 0.74)
|
0.65 (0.65, 0.89)
|
−0.22 (−0.38, −0.07)
|
|
CSA
|
AZA
|
3.20 (1.04, 10.19)
|
1.53 (1.53, 2.39)
|
0.26 (0.01, 0.47)
|
|
CYC LD
|
TAC
|
0.30 (0.09, 0.91)
|
0.50 (0.50, 0.95)
|
−0.28 (−0.50, −0.02)
|
|
PLASMA
|
CSA
|
0.19 (0.04, 0.92)
|
0.49 (0.49, 0.97)
|
−0.38 (−0.66, −0.02)
|
|
CYC LD
| |
0.13 (0.03, 0.52)
|
0.38 (0.38, 0.76)
|
−0.45 (−0.69, −0.15)
|
|
CYC HD
| |
0.23 (0.06, 0.72)
|
0.55 (0.55, 0.87)
|
−0.33 (−0.57, −0.08)
|
|
CYC HD
| |
0.23 (0.06, 0.72)
|
0.55 (0.55, 0.87)
|
−0.33 (−0.57, −0.08)
|
|
Random-effects model
|
Residual deviance
| |
82.2 vs. 77 data points
| |
| |
Deviance information criteria
| |
389.332
| |
|
Fixed-effects model
|
Residual Deviance
| |
88.8 vs. 77 data points
| |
| |
Deviance information criteria
| |
390.488
| |
- Based on 37 RCTs with 2697 patients: 35 two-arm trials and three three-arm trials
- aFor all comparisons of treatments of lupus nephritis for renal remission/response please see Appendix 5
- For absolute rates for events used for calculation of risk difference, please see Appendix 6
- OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab, HD high dose, LD low dose, when not specified, it indicates standard dose
- Significant odds ratios are in italics
- The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients
